Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters











Database
Language
Publication year range
1.
Integr Cancer Ther ; 19: 1534735420924757, 2020.
Article in English | MEDLINE | ID: mdl-32462950

ABSTRACT

Background: Integrative oncology has proven to be a useful approach to control cancer symptoms and improve the quality of life (QoL) and overall health of patients, delivering integrated patient care at both physical and emotional levels. The objective of this randomized trial was to evaluate the effects of a triple intervention program on the QoL and lifestyle of women with breast cancer. Methods: Seventy-five survivors of stage IIA-IIB breast cancer were randomized into 2 groups. The intervention group (IG) received a 6-month dietary, exercise, and mindfulness program that was not offered to the control group (CG). Data were gathered at baseline and at 6 months postintervention on QoL and adherence to Mediterranean diet using clinical markers and validated questionnaires. Between-group differences at baseline and 3 months postintervention were analyzed using Student's t test for related samples and the Wilcoxon and Mann-Whitney U tests. Results: At 6 months postintervention, the IG showed significant improvements versus CG in physical functioning (p = .027), role functioning (p = .028), and Mediterranean diet adherence (p = .02) and a significant reduction in body mass index (p = .04) and weight (p = .05), with a mean weight loss of 0.7 kg versus a gain of 0.55 kg by the CG (p = .05). Dyspnea symptoms were also increased in the CG versus IG (p = .066). Conclusions: These results demonstrate that an integrative dietary, physical activity, and mindfulness program enhances the QoL and healthy lifestyle of stage IIA-IIB breast cancer survivors. Cancer symptoms may be better managed by the implementation of multimodal rather than isolated interventions.


Subject(s)
Breast Neoplasms , Cancer Survivors , Diet, Mediterranean , Mindfulness , Exercise , Female , Humans , Quality of Life , Survivors
2.
Food Chem ; 322: 126676, 2020 Aug 30.
Article in English | MEDLINE | ID: mdl-32305871

ABSTRACT

To date, pharmacokinetics of maslinic (MA) and oleanolic (OA) acids, at normal dietary intakes in humans, have not been evaluated, and data concerning their bioactive effects are scarce. We assessed MA and OA pharmacokinetics after ingestion of olive oils (OOs) with high and low triterpenic acid contents, and specifically the effect of triterpenes on endothelial function. We performed a double-blind, dose-response, randomized, cross-over nutritional intervention in healthy adults, and observed that MA and OA increased in biological fluids in a dose-dependent manner. MA bioavailability was greater than that of OA, and consumption of pentacyclic triterpenes was associated with improved endothelial function. To the best of our knowledge, this is the first time MA pharmacokinetics, and effects on endothelial function in vivo, have been reported in humans.


Subject(s)
Oleanolic Acid/pharmacokinetics , Olive Oil/metabolism , Triterpenes/pharmacokinetics , Adult , Blood Pressure , Cross-Over Studies , Double-Blind Method , Endothelium/physiology , Female , Humans , Male , Middle Aged , Oleanolic Acid/blood , Oleanolic Acid/urine , Olive Oil/chemistry , Triterpenes/blood , Triterpenes/urine , Young Adult
3.
BMC Complement Altern Med ; 16(1): 404, 2016 Oct 22.
Article in English | MEDLINE | ID: mdl-27770787

ABSTRACT

BACKGROUND: Virgin olive oil, a recognized healthy food, cannot be consumed in great quantities. We aim to assess in humans whether an optimized virgin olive oil with high phenolic content (OVOO, 429 mg/Kg) and a functional one (FOO), both rich in phenolic compounds (429 mg/Kg) and triterpenic acids (389 mg/kg), could provide health benefits additional to those supplied a by a standard virgin olive oil (VOO). METHODS/DESIGN: A randomized, double-blind, crossover, controlled study will be conducted. Healthy volunteers (aged 20 to 50) will be randomized into one of three groups of daily raw olive oil consumption: VOO, OVOO, and FOO (30 mL/d). Olive oils will be administered over 3-week periods preceded by 2-week washout ones. The main outcomes will be markers of lipid and DNA oxidation, inflammation, and vascular damage. A bioavailability and dose-response study will be nested within this sustained- consumption one. It will be made up of 18 volunteers and be performed at two stages after a single dose of each olive oil. Endothelial function and nitric oxide will be assessed at baseline and at 4 h and 6 h after olive oil single dose ingestion. DISCUSSION: For the first time the NUTRAOLEUM Study will provide first level evidence on the health benefits in vivo in humans of olive oil triterpenes (oleanolic and maslinic acid) in addition to their bioavailability and disposition. TRIAL REGISTRATION: The Trial has been registered in ClinicalTrials.gov ID: NCT02520739 .


Subject(s)
Functional Food , Olive Oil , Phenols , Triterpenes , Adult , Biomarkers/blood , DNA Damage/drug effects , Humans , Inflammation/metabolism , Lipid Metabolism/drug effects , Middle Aged , Olive Oil/administration & dosage , Olive Oil/chemistry , Olive Oil/pharmacology , Oxidation-Reduction/drug effects , Phenols/administration & dosage , Phenols/chemistry , Phenols/pharmacology , Triterpenes/administration & dosage , Triterpenes/chemistry , Triterpenes/pharmacology , Young Adult
4.
Clin Breast Cancer ; 16(4): 262-8, 2016 08.
Article in English | MEDLINE | ID: mdl-26454613

ABSTRACT

BACKGROUND: We analyzed the toxicity and cosmetic outcomes for patients who had undergone 3-dimensional conformal radiotherapy with a hypofractionated schedule and identified the risk factors associated with such a schedule. MATERIALS AND METHODS: A total of 143 patients were treated for breast cancer (stage 0-III) with a hypofractionated radiation schedule after breast-conserving surgery from 2006 to 2011. Most patients received 42.4 Gy in 16 daily fractions, 2.65 Gy per fraction to the whole breast plus an additional simultaneous integrated or sequential boost to the tumor bed. RESULTS: The median follow-up period was 36 months. Mild acute skin toxicity was observed in 62%; 7% of the patients developed moderate skin toxicity, but no grade 4 toxicity was observed. The prevalence of fibrosis within the boost area was 5%, but no grade ≥ 2 was observed. The prevalence of fibrosis of any grade was greater in the nonboost (23%) than in the boost area. Of all the patients, 91% had good or excellent cosmetic outcomes. From the multivariate analysis, the incidence of epithelitis correlated with the patient's treated volume (P = .044). The incidence of acute toxicity correlated with the boost type to the tumor bed and the total treatment dose (P = .012 and P = .002, respectively). Also, a poor to fair cosmetic outcome was significantly associated statistically with the surgery type (P = .05), boost type (P = .004), and total dose (P = .001). CONCLUSION: Delivering whole-breast irradiation with a hypofractionated schedule of 42.4 Gy plus a simultaneous integrated boost to the tumor bed appears to be a safe and effective technique, with good cosmetic results and lower toxicity.


Subject(s)
Breast Neoplasms/radiotherapy , Radiation Dose Hypofractionation , Radiation Injuries/epidemiology , Radiotherapy, Adjuvant/methods , Skin/radiation effects , Aged , Aged, 80 and over , Breast Neoplasms/pathology , Breast Neoplasms/surgery , Feasibility Studies , Female , Fibrosis , Follow-Up Studies , Humans , Mastectomy, Segmental , Middle Aged , Neoplasm Staging , Prevalence , Radiotherapy, Conformal/methods , Risk Factors , Skin/pathology , Treatment Outcome
5.
J Rheumatol ; 41(3): 453-7, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24488423

ABSTRACT

OBJECTIVE: To compare the prevalence and disability of headache in patients with systemic lupus erythematosus (SLE) with the general population and to assess the role of chronic psychological stress (CPS) in headache development. METHODS: One hundred seventy patients with SLE and 102 control subjects matched for age, sex, and level of education were included in this multicenter, cross-sectional study. CPS, headache-related disability, and chronic analgesic intake (CAI) were evaluated in all participants. RESULTS: No statistical differences in the prevalence of headache between both groups were observed but headache disability was significantly higher in patients with SLE. In addition, a higher average score in the Cohen Perceived Stress Scale (CPSS) and a higher prevalence of patients with CAI were observed in patients with SLE. In multivariate analysis, CPSS score was positively (OR 1.09; 95% CI: 1.03-1.14; p = 0.001) and CAI negatively (OR 0.43; 95% CI: 0.19-0.99; p = 0.049) associated with headache in patients with SLE. CONCLUSION: Despite the prevalence of headache in patients with SLE and the general population being similar, headache-related disability may be higher in patients with SLE. Moreover, CPS might play a role in the pathogenesis of SLE headache, whereas CAI might have a protective effect against it.


Subject(s)
Headache/epidemiology , Headache/etiology , Lupus Erythematosus, Systemic/complications , Stress, Psychological/complications , Adult , Cross-Sectional Studies , Female , Headache/psychology , Humans , Lupus Erythematosus, Systemic/psychology , Male , Middle Aged , Prevalence , Stress, Psychological/psychology
SELECTION OF CITATIONS
SEARCH DETAIL